LinusBio Raises $16M in Series A Funding

LinusBio

LinusBio, a New York-based company providing precision exposome sequencing, raised $16M in Series A funding.

The round was led by GreatPoint Ventures and Bow Capital with participation from Divergent Investments, Nicole Shanahan, the David Bellet Family Office, Gillian Sandler, and Sanford Robertson.

The company intends to use the funds to accelerate growth of its team, deliver more positive outcomes across more health conditions, and develop a platform that will serve as a central hub for diagnostics and treatment.

Led by CEO Manish Arora, LinusBio is a patient-centric, science precision exposome medicine company. Its program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.

LinusBio’s technology examines human physiology at the molecular level through a strand of hair. Leveraging proprietary laser and robotics technology, LinusBio analyzes these strands and collects thousands of data points to measure individuals’ biological response to their lifespan environmental exposures.

The company’s initial focus is on neurological disorders. The company’s program pipeline also comprises advanced biomarkers for ALS, oncology (including pediatric cancer), gastroenterology (inflammatory bowel disease) and mental disorders (psychosis & schizophrenia).

FinSMEs

13/01/2023